National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 83507-83508 [2024-23836]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 200 / Wednesday, October 16, 2024 / Notices
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Velasco Cimica, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–1760, velasco.cimica@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Musculoskeletal Sciences in
Diagnostics, Devices, and Rehabilitation.
Date: November 12–13, 2024.
Time: 8:00 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: Melrose Hotel, 2430 Pennsylvania
Ave. NW, Washington, DC 20037.
Meeting Format: In Person.
Contact Person: Amber Taylor Collins,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 827–5245, amber.collins@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Applied Immunology and Vaccine
Development.
Date: November 12–13, 2024.
Time: 8:30 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Meeting Format: In Person.
Contact Person: Dayadevi Jirage, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4422,
Bethesda, MD 20892, (301) 867–5309,
jiragedb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: Cancer Diagnosis and Treatments
(CDT).
Date: November 12–13, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Victor A. Panchenko,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 802B2,
Bethesda, MD 20892, (301) 867–5309,
victor.panchenko@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis; Panel
Fellowships: Vascular and Hematological
Systems, Surgical Sciences, Biomedical
Imaging, and Bioengineering.
Date: November 12–13, 2024.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
VerDate Sep<11>2014
16:43 Oct 15, 2024
Jkt 265001
83507
Contact Person: Courtney Elaine Watkins,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 496–3093, courtney.watkins2@
nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Infectious Disease and
Immunology A.
Date: November 12–13, 2024.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Maria Chiara G. MonacoKushner, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Dr.,
Bethesda, MD 20892, (301) 555–1212,
monaco@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Behavioral Neuroscience.
Date: November 12–13, 2024.
Time: 10:00 a.m. to 8:30 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: John Drake Morgan, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Dr., Room 1015A,
Bethesda, MD 20892, (301) 827–9283,
morganjod@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Center of Excellence for
Systems Modeling of Infection and Immunity
across Biological Scales (U54 Clinical Trial
Not Allowed).
Date: November 21–22, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G45,
Rockville, MD 20892 (Video Assisted
Meeting).
Contact Person: Vanitha Sundaresa Raman,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G45, Rockville, MD
20892, 301–761–7949, vanitha.raman@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 10, 2024.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
[FR Doc. 2024–23874 Filed 10–15–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Dated: October 10, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–23838 Filed 10–15–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Division of Intramural
Research Board of Scientific Counselors,
NIAID.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), title 5 U.S.C., as amended for
the review, discussion, and evaluation
of individual intramural programs and
projects conducted by the National
Institute of Allergy and Infectious
Diseases, including consideration of
personnel qualifications and
performance, and the competence of
individual investigators, the disclosure
E:\FR\FM\16OCN1.SGM
16OCN1
83508
Federal Register / Vol. 89, No. 200 / Wednesday, October 16, 2024 / Notices
of which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Division of Intramural
Research Board of Scientific Counselors,
NIAID.
Date: December 9–11, 2024.
Time: 8:00 a.m. to 10:15 a.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Address: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, Building 50, Conference Room 1227/
1233, 50 Center Drive, Bethesda, MD 20892.
Contact Person: Laurie Lewallen,
Committee Manager, Division of Intramural
Research, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, Building 33, Room 1N24, 33 North
Drive, Bethesda, MD 20892, 301–761–6362,
Laurie.Lewallen@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 10, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–23836 Filed 10–15–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Microglial Pathophysiology in Comorbid
Substance Use Disorder (SUD) and HIV.
Date: November 5, 2024.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
VerDate Sep<11>2014
16:43 Oct 15, 2024
Jkt 265001
Contact Person: Meysam Yazdankhah,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Office of Extramural Policy,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 402–6965,
meysam.yazdankhah@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Mechanistic Studies on Social Behavior in
Substance Use Disorder.
Date: November 19, 2024.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Caitlin Elizabeth Angela
Moyer, Ph.D., Scientific Review Officer,
Scientific Review Branch, Office of
Extramural Policy, National Institute on Drug
Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 443–
4577, caitlin.moyer@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; High
Priority HIV and Substance Use Research.
Date: November 20, 2024.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Address: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892.
Meeting Format: Virtual Meeting.
Contact Person: Trinh T. Tran, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Office of Extramural Policy, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 827–5843, trinh.tran@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
ACTION:
Dated: October 10, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
I. Public Participation
Interested persons are invited to
comment on this notice by submitting
written data, views, or arguments using
the method identified in the
aforementioned ADDRESSES section. All
members of the public including, but
not limited to, specialists in the field,
academic experts, members of industry,
public interest groups, and those with
relevant economic expertise are invited
to comment.
[FR Doc. 2024–23837 Filed 10–15–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. CISA–2024–0028]
Request for Comment on Product
Security Bad Practices Guidance
Cybersecurity and
Infrastructure Security Agency (CISA),
Department of Homeland Security
(DHS).
AGENCY:
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Notice of availability; request
for comment.
The Cybersecurity Division
(CSD) within the Cybersecurity and
Infrastructure Security Agency (CISA)
requests feedback on draft Product
Security Bad Practices guidance.
Additionally, CISA requests input on
analysis or approaches currently absent
from the guidance.
DATES: Written comments are requested
on or before December 2, 2024.
Submissions received after the deadline
for receiving comments may not be
considered.
ADDRESSES: You may submit comments,
identified by docket number CISA–
2024–0028, by following the
instructions below for submitting
comments via the Federal eRulemaking
Portal at https://www.regulations.gov.
Instructions: All comments received
must include the agency name and
docket number Docket Number CISA–
2024–0028. All comments received will
be posted without change to https://
www.regulations.gov, including any
personal information provided. CISA
reserves the right to publicly republish
relevant and unedited comments in
their entirety that are submitted to the
docket. Do not include personal
information such as account numbers,
social security numbers, or the names of
other individuals. Do not submit
confidential business information or
otherwise sensitive or protected
information.
Docket: For access to the docket to
read the draft Product Security Bad
Practices Guidance or comments
received, go to https://
www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Kirk
Lawrence; 202–617–0036;
SecureByDesign@cisa.dhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
II. Background
In line with CISA’s Secure by Design
initiative, software manufacturers
should ensure security is a core
consideration from the onset of software
development. CISA’s draft, voluntary
E:\FR\FM\16OCN1.SGM
16OCN1
]]>Agencies
[Federal Register Volume 89, Number 200 (Wednesday, October 16, 2024)]
[Notices]
[Pages 83507-83508]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-23836]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Division of
Intramural Research Board of Scientific Counselors, NIAID.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the National
Institute of Allergy and Infectious Diseases, including consideration
of personnel qualifications and performance, and the competence of
individual investigators, the disclosure
[[Page 83508]]
of which would constitute a clearly unwarranted invasion of personal
privacy.
Name of Committee: Division of Intramural Research Board of
Scientific Counselors, NIAID.
Date: December 9-11, 2024.
Time: 8:00 a.m. to 10:15 a.m.
Agenda: To review and evaluate personnel qualifications and
performance, and competence of individual investigators.
Address: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, Building 50, Conference Room 1227/
1233, 50 Center Drive, Bethesda, MD 20892.
Contact Person: Laurie Lewallen, Committee Manager, Division of
Intramural Research, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Building 33, Room 1N24, 33
North Drive, Bethesda, MD 20892, 301-761-6362,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: October 10, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-23836 Filed 10-15-24; 8:45 am]
BILLING CODE 4140-01-P
